Severe pulmonary hypertension: The role of metabolic and endocrine disorders

Pulmonary Circulation

Volumn 2, Issue 2, 2012, Pages 148-154

  Bogaard, Harm J ^a   Al Husseini, Aysar ^b   Farkas, Laszlo ^b   Farkas, Daniela ^b   Gomez Arroyo, Jose ^b   Abbate, Antonio ^b   Voelkel, Norbert F ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Epigenetics; Gender; Obesity; Pulmonary hypertension; Right heart failure; Thyroid

Indexed keywords

EID: 84888242708     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.97592     Document Type: Review

References (60)

1. Imonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
2. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010;6:431-43.
3. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
4. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
5. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
6. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63.
7. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-9.
8. Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ 2011;1:305-19.
9. Sweeney L, Voelkel N. Estrogen exposure, obesity and thyroid disease is women with severe pulmonary hypertension. Eur J Med Res 2009;14:433-42.
10. Taraseviciute A, Voelkel NF. Severe pulmonary hypertension in postmenopausal obese women. Eur J Med Res 2006;11:198-202.
11. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011;139:128-37.
12. Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway C, Groves BM. Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link? Ann Intern Med 1993;119:44-6.
13. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999;318:289-92.
14. Arroliga AC, Dweik RA, Rafanan AL. Primary pulmonary hypertension and thyroid disease. Chest 2000;118:1224-5.
15. Ferris A, Jacobs T, Widlitz A, Barst RJ, Morse JH. Pulmonary arterial hypertension and thyroid disease. Chest 2001;119:1980-1.
16. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012;141:363-73
17. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: A perspective. Eur Respir J 2005;26:1110-8.
18. Sweeney L, Chhatwani L. Endocrine aspects of pulmonary hypertension. Pulmonary hypertension: Present and Future (NF Voelkel, ed). Shelton, Connecticut: People’s Medical Publishing House; 2011. p. 239-49.
19. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794-804.
20. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-68.
21. Siervo M, Ruggiero D, Sorice R, Nutile T, Aversano M, Iafusco M, et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition 2012;28:262-6
22. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886-95.
23. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010;106: 284-6.
24. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
25. El-Husseini AA, Sobh MA, Ghoneim MA. Complications of pediatric livedonor kidney transplantation: a single center’s experience in Egypt. Pediatr Nephrol 2008;23:2067-73.
26. Gallagher J, Sai A. Vitamin D insuffiency, deficiency, and bone health. J Clin Endocrinol Metab 2010;95:2630-3.
27. Gonzalez-Pardo V, Martin D, Gutkind JS, Verstuyf A, Bouillon R, de Boland AR, et al. 1 Alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcomaassociated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 2010;151:23-31.
28. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 2011;12:54-60.
29. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012;76:315-25.
30. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007;6:1433-9.
31. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011;70:145-50.
32. Ulrich S, Hersberger M, Fischler M, Huber LC, Senn O, Treder U, et al. Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension. Open Respir Med J 2009;3:53-60.
33. Brunner S, Zaruba MM, Huber B, David R, Vallaster M, Assmann G, et al. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol 2008;36:1157-66.
34. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 2008;38:798-803.
35. Di Bernardo G, Galderisi U, Fiorito C, Squillaro T, Cito L, Cipollaro M, et al. Dual role of parathyroid hormone in endothelial progenitor cells and marrow stromal mesenchymal stem cells. J Cell Physiol 2010;222:474-80.
36. Chhatwani L, Xu X, Veenstra T, Voelkel N, Sweeney L. Serum estrogen metabolites in severe pulmonary arterial hypertension. Am J Crit Care Med 2010;181:A4860.
37. Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med 2006;17:267-71.
38. Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: A prospective echocardiographic study. J Clin Endocrinol Metab 2007;92:1736-42.
39. Guntekin U, Gunes Y, Tuncer M, Simsek H, Gumrukcuoglu HA, Arslan S, et al. QTc dispersion in hyperthyroidism and its association with pulmonary hypertension. Pacing Clin Electrophysiol 2009;32:494-9.
40. Merce J, Ferras S, Oltra C, Sanz E, Vendrell J, Simon I, et al. Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study. Am J Med 2005;118:126-31.
41. Armigliato M, Paolini R, Aggio S, Zamboni S, Galasso MP, Zonzin P, et al. Hyperthyroidism as a cause of pulmonary arterial hypertension: A prospective study. Angiology 2006;57:600-6.
42. Yazar A, Doven O, Atis S, Gen R, Pata C, Yazar EE, et al. Systolic pulmonary artery pressure and serum uric acid levels in patients with hyperthyroidism. Arch Med Res 2003;34:35-40.
43. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 2007;88:271-7.
44. Lin HY, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J 1999;338:427-32.
45. Al Hussaini AA, Bagnato G, Farkas L, Gomez-Arroyo J, Farkas D, Mizuno S, et al. Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats. Eur Resp J 2012 (in press).
46. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-9.
47. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-7.
48. Nicolls MR, Voelkel NF. Hypoxia and the lung: Beyond hypoxic vasoconstriction. Antioxid Redox Signal 2007;9:741-3.
49. Yeager ME, Frid MG, Stenmark KR. Progenitor cells in pulmonary vascular remodeling. Pulm Circ 2011;1:3-16.
50. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 2001; 15: 427-38.
51. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-80.
52. Bogaard H, Mizuno S, Guignabert C, Al Hussaini A, Farkas D, Ruiter G, et al. Copper-dependence of angioproliferation in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2011 Dec 28. [Epub ahead of print].
53. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-54.
54. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, et al. Rho Kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100:923-9.
55. Lemon DD, Horn TR, Cavasin MA, Jeong MY, Haubold KW, Long CS, et al. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol 2011;51:41-50.
56. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-76.
57. Barrera-Hernandez G, Zhan Q, Wong R, Cheng SY. Thyroid hormone receptor is a negative regulator in p53-mediated signaling pathways. DNA Cell Biol 1998;17:743-50.
58. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is antiapoptotic. Steroids 2007;72:180-7.
59. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 2011;51:99-115.
60. Bhupathy P, Haines CD, Leinwand LA. Influence of sex hormones and phytoestrogens on heart disease in men and women. Womens Health (Lond Engl) 2010;6:77-95.